Bio-Path (BPTH) Competitors $1.26 -0.23 (-15.44%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends BPTH vs. RLMD, CRVO, KZIA, KPRX, TLPH, SNSE, TSBX, PHXM, JAGX, and INDPShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include Relmada Therapeutics (RLMD), CervoMed (CRVO), Kazia Therapeutics (KZIA), Kiora Pharmaceuticals (KPRX), Talphera (TLPH), Sensei Biotherapeutics (SNSE), Turnstone Biologics (TSBX), PHAXIAM Therapeutics (PHXM), Jaguar Health (JAGX), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Relmada Therapeutics CervoMed Kazia Therapeutics Kiora Pharmaceuticals Talphera Sensei Biotherapeutics Turnstone Biologics PHAXIAM Therapeutics Jaguar Health Indaptus Therapeutics Relmada Therapeutics (NASDAQ:RLMD) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Which has more risk and volatility, RLMD or BPTH? Relmada Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Which has stronger valuation and earnings, RLMD or BPTH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$98.79M-$2.87-0.13Bio-PathN/AN/A-$16.08MN/AN/A Does the MarketBeat Community favor RLMD or BPTH? Bio-Path received 265 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 54.23% of users gave Bio-Path an outperform vote while only 37.78% of users gave Relmada Therapeutics an outperform vote. CompanyUnderperformOutperformRelmada TherapeuticsOutperform Votes1737.78% Underperform Votes2862.22% Bio-PathOutperform Votes28254.23% Underperform Votes23845.77% Do insiders and institutionals hold more shares of RLMD or BPTH? 45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 18.0% of Relmada Therapeutics shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate RLMD or BPTH? Relmada Therapeutics currently has a consensus price target of $4.25, suggesting a potential upside of 1,071.12%. Bio-Path has a consensus price target of $20.00, suggesting a potential upside of 1,487.30%. Given Bio-Path's stronger consensus rating and higher probable upside, analysts plainly believe Bio-Path is more favorable than Relmada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is RLMD or BPTH more profitable? Relmada Therapeutics' return on equity of -129.80% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -129.80% -112.06% Bio-Path N/A -2,842.40%-337.48% Does the media prefer RLMD or BPTH? In the previous week, Bio-Path had 30 more articles in the media than Relmada Therapeutics. MarketBeat recorded 30 mentions for Bio-Path and 0 mentions for Relmada Therapeutics. Bio-Path's average media sentiment score of 0.12 beat Relmada Therapeutics' score of 0.00 indicating that Bio-Path is being referred to more favorably in the news media. Company Overall Sentiment Relmada Therapeutics Neutral Bio-Path Neutral SummaryBio-Path beats Relmada Therapeutics on 7 of the 12 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.43M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / SalesN/A195.801,117.00116.99Price / CashN/A57.1642.9637.86Price / Book1.775.094.784.78Net Income-$16.08M$151.83M$120.31M$225.60M7 Day Performance90.56%-2.13%-1.92%-1.23%1 Month Performance57.70%-3.10%11.50%3.36%1 Year Performance-85.52%11.54%30.59%16.60% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path2.4974 of 5 stars$1.26-15.4%$20.00+1,487.3%-85.1%$5.43MN/A0.0010Analyst ForecastNews CoverageGap DownHigh Trading VolumeRLMDRelmada Therapeutics4.1808 of 5 stars$0.40+8.4%$4.25+967.8%-85.2%$12.01MN/A-0.1310Gap DownHigh Trading VolumeCRVOCervoMed2.2198 of 5 stars$1.94+2.1%$42.00+2,065.1%-67.6%$11.97M$7.14M0.004Analyst DowngradeAnalyst RevisionHigh Trading VolumeKZIAKazia Therapeutics1.7324 of 5 stars$3.58+0.8%$20.00+458.7%-25.4%$11.92M$2.31M0.0012Gap UpKPRXKiora Pharmaceuticals2.1069 of 5 stars$3.84+15.7%$10.00+160.4%-32.2%$11.52M$16M0.0010Positive NewsGap UpTLPHTalphera2.886 of 5 stars$0.66+2.1%$4.50+578.2%N/A$11.30M$281,000.00-0.9419Positive NewsSNSESensei Biotherapeutics4.0699 of 5 stars$0.44-0.6%$4.33+890.7%-28.0%$11.00MN/A-0.3740TSBXTurnstone Biologics2.849 of 5 stars$0.47-1.9%$2.13+351.2%-79.7%$10.89M$19.31M-0.1582PHXMPHAXIAM TherapeuticsN/A$3.10-0.6%N/AN/A$10.58M$32.66M0.0049JAGXJaguar Health0.2557 of 5 stars$0.89-8.6%N/A-89.7%$10.46M$9.76M0.0050News CoverageGap UpINDPIndaptus Therapeutics2.868 of 5 stars$1.00flat$8.50+750.0%-49.0%$10.20MN/A-0.586 Related Companies and Tools Related Companies RLMD Alternatives CRVO Alternatives KZIA Alternatives KPRX Alternatives TLPH Alternatives SNSE Alternatives TSBX Alternatives PHXM Alternatives JAGX Alternatives INDP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BPTH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPTH Stock Alerts